Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

Halfway there: the past, present and future of haploidentical transplantation

Bone Marrow Transplantation volume 52, pages 1–6 (2017)Cite this article

Subjects

Abstract

In recent years, the use of haploidentical donors for hematopoietic cell transplantation has expanded rapidly. Approximately 50% of patients requiring hematopoietic cell transplant lack a traditional donor. The use of HLA haploidentical-related donors is attractive due to nearly universal availability of this graft source. We summarize the current and future need for haploidentical donors and detail the rise of post-transplant cyclophosphamide as the dominant haploidentical approach. Further, we examine ongoing controversies in the field of haploidentical transplant, including conditioning regimens and graft source. Finally, we review the evidence available from preliminary comparative studies and discuss future direction of research.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Beatty PG, Dahlberg S, Mickelson EM, Nisperos B, Opelz G, Martin PJ et al. Probability of finding HLA-matched unrelated marrow donors. Transplantation 1988; 45: 714–718.

    Article  CAS  PubMed  Google Scholar 

  2. Besse K, Maiers M, Confer D, Albrecht M . On modeling human leukocyte antigen–identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source. Biol Blood Marrow Transplant 2015; 22: 1–8.

    Google Scholar 

  3. Martin JA, Hamilton BE, Osterman MJ, Curtin SC, Matthews TJ . Births: final data for 2013. Natl Vital Stat Rep 2015; 64: 1–65.

    PubMed  Google Scholar 

  4. van Agthoven M, Groot MT, Verdonck LF, Löwenberg B, Schattenberg AVMB, Oudshoorn M et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant 2002; 30: 243–251.

    Article  CAS  PubMed  Google Scholar 

  5. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 2014; 371: 339–348.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V et al. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant 2012; 48: 346–350.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Morishima Y, Kashiwase K, Matsuo K, Azuma F, Morishima S, Onizuka M et al. Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. Blood 2015; 125: 1189–1198.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576–4583.

    Article  CAS  PubMed  Google Scholar 

  9. Fuchs EJ . Haploidentical transplantation for hematologic malignancies: where do we stand? Hematology Am Soc Hematol Educ Program 2012; 2012: 230–236.

    PubMed  Google Scholar 

  10. Bashey A, Solomon SR . T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant 2014; 49: 999–1008.

    Article  CAS  PubMed  Google Scholar 

  11. Fuchs EJ . Human leukocyte antigen-haploidentical stem cell transplantation using T-cell-replete bone marrow grafts. Curr Opin Hematol 2012; 19: 440–447.

    Article  CAS  PubMed  Google Scholar 

  12. Powles RL, Morgenstern GR, Kay HE, McElwain TJ, Clink HM, Dady PJ et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1983; 1: 612–615.

    Article  CAS  PubMed  Google Scholar 

  13. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765–771.

    Article  CAS  PubMed  Google Scholar 

  14. Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990; 29: 79–91.

    Article  CAS  PubMed  Google Scholar 

  15. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767–1777.

    Article  CAS  PubMed  Google Scholar 

  16. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C et al. Successful engraftment of T-cell-depleted haploidentical ‘three-loci’ incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948–3955.

    CAS  PubMed  Google Scholar 

  17. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186–1193.

    Article  CAS  PubMed  Google Scholar 

  18. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–3454.

    Article  PubMed  Google Scholar 

  19. Berenbaum MC, Brown IN . Prolongation of homograft survival in mice with single doses of cyclophosphamide. Nature 1963; 200: 84.

    Article  CAS  PubMed  Google Scholar 

  20. Colson YL, Wren SM, Schuchert MJ, Patrene KD, Johnson PC, Boggs SS et al. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. J Immunol 1995; 155: 4179–4188.

    CAS  PubMed  Google Scholar 

  21. Colson YL, Li H, Boggs SS, Patrene KD, Johnson PC, Ildstad ST . Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. J Immunol 1996; 157: 2820–2829.

    CAS  PubMed  Google Scholar 

  22. Owens AHJ, Santos GW . The effect of cytotoxic drugs on graft-versus-host disease in mice. Transplantation 1971; 11: 378–382.

    Article  CAS  PubMed  Google Scholar 

  23. Robinson TM, O’Donnell PV, Fuchs EJ, Luznik L . Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol 2016; 53: 90–97.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Kanakry CG, Ganguly S, Zahurak M, Bolaños-Meade J, Thoburn C, Perkins B et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 2013; 5: 211ra157.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. O’Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8: 377–386.

    Article  PubMed  Google Scholar 

  26. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1835–1844.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Luger SM, Ringdén O, Zhang M-J, Pérez WS, Bishop MR, Bornhauser M et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47: 203–211.

    Article  CAS  PubMed  Google Scholar 

  29. Solomon SR, Sizemore Ca, Sanacore M, Zhang X, Brown S, Holland HK et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival. Biol Blood Marrow Transplant 2012; 18: 1859–1866.

    Article  PubMed  Google Scholar 

  30. Solomon SR, Sizemore Ca, Sanacore M, Zhang X, Brown S, Holland HK et al. Total body irradiation–based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant 2015; 21: 1299–1307.

    Article  PubMed  Google Scholar 

  31. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013; 19: 117–122.

    Article  CAS  PubMed  Google Scholar 

  32. Symons HJ, Chen A, Gamper C, Cooke KR, Showel M, Bolaños-Meade J et al. Haploidentical BMT using fully myeloablative conditioning, T cell replete bone marrow grafts, and post-transplant cyclophosphamide (PT/CY) has limited toxicity and promising efficacy in largest reported experience with high risk hematologic malignancies. Biol Blood Marrow Transplant 2015; 21: S29.

    Article  Google Scholar 

  33. Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013; 121: 849–857.

    Article  CAS  PubMed  Google Scholar 

  34. Solomon SR, Solh M, Morris LE, Holland HK, Bashey A . Myeloablative conditioning with PBSC grafts for T cell-replete haploidentical donor transplantation using posttransplant cyclophosphamide. Adv Hematol 2016; 2016: 1–7.

    Article  CAS  Google Scholar 

  35. Pingali SR, Milton D, Di Stasi A, Patel RD, Kebriaei P, Popat UR et al. Haploidentical transplantation for advanced hematologic malignancies using melphalan-based conditioning-mature results from a single center. Biol Blood Marrow Transplant 2014; 20: S40–S41.

    Article  Google Scholar 

  36. HRSA. Donor Registry Transplant Data. Available at: http://bloodcell.transplant.hrsa.gov/research/transplant_Data/registry_TX_data/index.html. Accessed on 2 April 2016.

  37. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487–1496.

    Article  CAS  PubMed  Google Scholar 

  38. Sengsayadeth S, Savani BN, Blaise D, Mohty M . Haploidentical transplantation: selecting optimal conditioning regimen and stem cell source. Semin Hematol 2016; 53: 111–114.

    Article  PubMed  Google Scholar 

  39. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231–1237.

    Article  CAS  PubMed  Google Scholar 

  40. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181.

    Article  CAS  PubMed  Google Scholar 

  41. Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the soeiete francaise de greffe de moelle. J Clin Oncol 2000; 18: 537–546.

    Article  CAS  PubMed  Google Scholar 

  42. Mielcarek M, Storer B, Martin PJ, Forman SJ, Negrin RS, Flowers ME et al. Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. Blood 2012; 119: 2675–2678.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Stem Cell Trialists’ Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074–5087.

    Article  Google Scholar 

  44. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH . Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685–3691.

    Article  CAS  PubMed  Google Scholar 

  45. Schmitz N, Eapen M, Horowitz MM, Zhang M-J, Klein JP, Rizzo JD et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 4288–4290.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol 2010; 11: 331–338.

    Article  PubMed  Google Scholar 

  47. Ciurea SO, Zhang M-J, Bacigalupo Aa, Bashey A, Appelbaum FR, Aljitawi OS et al. Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia. Blood 2015; 126: 1033–1040.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014; 20: 890–895.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Sugita J, Kawashima N, Fujisaki T, Kakihana K, Ota S, Matsuo K et al. HLA-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after Busulfan-containing reduced-intensity conditioning. Biol Blood Marrow Transplant 2015; 21: 1646–1652.

    Article  PubMed  Google Scholar 

  50. Bhamidipati PK, DiPersio JF, Stokerl-Goldstein K, Rashidi A, Gao F, Uy GL et al. Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes. Bone Marrow Transplant 2014; 49: 1124–1126.

    Article  CAS  PubMed  Google Scholar 

  51. Grosso D, Carabasi M, Filicko-O’Hara J, Kasner M, Wagner JL, Colombe B et al. A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood 2011; 118: 4732–4739.

    Article  CAS  PubMed  Google Scholar 

  52. Grosso D, Gaballa S, Alpdogan O, Carabasi M, Filicko-O’Hara J, Kasner M et al. A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease. Biol Blood Marrow Transplant 2015; 21: 646–652.

    Article  PubMed  Google Scholar 

  53. Castagna L, Crocchiolo R, Furst S, Bramanti S, El Cheikh J, Sarina B et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014; 20: 724–729.

    Article  PubMed  Google Scholar 

  54. Kekre N, Antin JH . Cord blood versus haploidentical stem cell transplantation for hematological malignancies. Semin Hematol 2016; 53: 98–102.

    Article  PubMed  Google Scholar 

  55. Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011; 118: 282–288.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Raiola AM, Dominietto A, di Grazia C, Lamparelli T, Gualandi F, Ibatici A et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 2014; 20: 1573–1579.

    Article  PubMed  Google Scholar 

  57. Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia 2015; 29: 1891–1900.

    Article  CAS  PubMed  Google Scholar 

  58. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen–matched unrelated and related donors. Biol Blood Marrow Transplant 2014; 20: 1975–1981.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Gaballa S, Palmisiano N, Alpdogan O, Carabasi M, Filicko-O’Hara J, Kasner M et al. A two-step haploidentical versus a two-step matched related allogeneic myeloablative peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2016; 22: 141–148.

    Article  PubMed  Google Scholar 

  60. Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013; 31: 1310–1316.

    Article  CAS  PubMed  Google Scholar 

  61. Burroughs LM, O’Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1279–1287.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched unrelated donors. Blood 2015; 127: 938–947.

    Article  CAS  PubMed  Google Scholar 

  63. Chang Y-J, Huang X-J . Haploidentical stem cell transplantation: anti-thymocyte globulin-based experience. Semin Hematol 2016; 53: 82–89.

    Article  CAS  PubMed  Google Scholar 

  64. Huang X-J, Liu D-H, Liu K-Y, Xu L-P, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291–297.

    Article  PubMed  Google Scholar 

  65. Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood 2014; 124: 843–850.

    Article  CAS  PubMed  Google Scholar 

  66. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 2015; 125: 3956–3962.

    Article  CAS  PubMed  Google Scholar 

  67. Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MTL et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 2014; 29: 1–10.

    Google Scholar 

  68. Shin SH, Kim JH, Jeon YW, Yoon JH, Yahng SA, Lee SE et al. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome. Biol Blood Marrow Transplant 2015; 21: 342–349.

    Article  CAS  PubMed  Google Scholar 

  69. Perruccio K, Topini F, Tosti A, Carotti A, Aloisi T, Aversa F et al. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol Dis 2008; 40: 76–83.

    Article  CAS  PubMed  Google Scholar 

  70. Bastien JP, Krosl G, Therien C, Rashkovan M, Scotto C, Cohen S et al. Photodepletion differentially affects CD4+ Tregs versus CD4+effector T cells from patients with chronic graft-versus-host disease. Blood 2010; 116: 4859–4869.

    Article  CAS  PubMed  Google Scholar 

  71. Perruccio K, Topini F, Tosti A, Carotti A, Burchielli E, Ruggeri L et al. Optimizing a photoallodepletion protocol for adoptive immunotherapy after haploidentical SCT. Bone Marrow Transplant 2012; 47: 1196–1200.

    Article  CAS  PubMed  Google Scholar 

  72. Roy D, Lachance S, Kiss T, Cohen S, Busque L, Fish D et al. Haploidentical stem cell transplantation: High doses of alloreactive-T cell depleted donor lymphocytes administered post-transplant decrease infections and improve survival without causing severe Gvhd. Blood 2009; 114: 512.

    Google Scholar 

  73. Roy D, Maertens J, IWalker I, Lachance S, Roy J, Foley S et al. Selective photodepletion of recipient-alloreactive T-cells enables safe and efficacious haploidentical HSCT: initial results from a phase 2 trial in patients with AML, ALL, and MDS. Blood 2014; 124: 314.

    Google Scholar 

  74. Schumm M, Lang P, Bethge W, Faul C, Feuchtinger T, Pfeiffer M et al. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy 2013; 15: 1253–1258.

    Article  CAS  PubMed  Google Scholar 

  75. Airoldi I, Bertaina A, Prigione I, Zorzoli A, Pagliara D, Cocco C et al. Gammadelta T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-alphabeta+/CD19+ lymphocytes. Blood 2015; 125: 2349–2358.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Lang P, Feuchtinger T, Teltschik H-M, Schwinger W, Schlegel P, Pfeiffer M et al. Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients. Bone Marrow Transplant 2015; 50: S6–S10.

    Article  CAS  PubMed  Google Scholar 

  77. McCurdy SR, Kanakry JA, Showel MM, Tsai H-L, Bolaños-Meade J, Rosner GL et al. Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015; 125: 3024–3031.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Blaise D, Fürst S, Crocchiolo R, El-Cheikh J, Granata A, Harbi S et al. Haploidentical T cell–replete transplantation with post-transplantation cyclophosphamide for patients in or above the sixth decade of age compared with allogeneic hematopoietic stem cell transplantation from an human leukocyte antigen–matched related or unrelated donor. Biol Blood Marrow Transplant 2016; 22: 119–124.

    Article  PubMed  Google Scholar 

  79. Kasamon YL, Bolanos-Meade J, Prince GT, Tsai H-L, McCurdy SR, Kanakry JA et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol 2015; 33: 3152–3161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012; 120: 4285–4291.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Slade M, Goldsmith SR, Romee R, DiPersio JF, Dubberke E, Westervelt P et al. Infectious complications after peripheral blood (PB) haploidentical hematopoietic cell transplantation (haplo-HCT). Biol Blood Marrow Transplant 2016; 22: S176–S177.

    Article  Google Scholar 

  82. Crocchiolo R, Bramanti S, Vai A, Sarina B, Mineri R, Casari E et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis 2015; 17: 242–249.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Goldsmith SR, Slade M, Lawrence SJ, DiPersio JF, Westervelt P, Uy GL et al. Cytomegalovirus viremia and relapse after haploidentical hematopoietic cell transplantation. Biol Blood Marrow Transplant 2016; 22: S320.

    Article  Google Scholar 

  84. Ramlal R, Sasaki K, Cerrada SL, Srour SA, Chen J, Rondon RG et al. Viral reactivation in haploidentical transplants using post-transplantation cyclophosphamide - a single institution experience. Biol Blood Marrow Transplant 2016; 22: S375–S376.

    Article  Google Scholar 

  85. Roberto A, Castagna L, Zanon V, Bramanti S, Crocchiolo R, McLaren JE et al. Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. Blood 2015; 125: 2855–2865.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Cieri N, Oliveira G, Greco R, Forcato M, Taccioli C, Cianciotti B et al. Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. Blood 2015; 125: 2865–2874.

    Article  CAS  PubMed  Google Scholar 

  87. Pérez-Corral AM, Champ D, Anguita J, Pascual C, Gayoso J, Bastos-Oreiro M et al. Delayed reconstitution and immature phenotype of natural killer(NK) cells following postransplant cyclophospamide in 30 unmanipulated haploidentical transplantation patients. A prospective analysis. Haematologica 2015; 100: 610–611.

    Google Scholar 

  88. Jaiswal S, Chakrabarti A, Chatterjee S, Ray K, O’Donnell P, Chakrabarti S . Early donor lymphocyte infusion and NK ligand mismatched donor might improve the outcome of relapsed/refractory acute myeloid leukemia following posttransplantation cyclophosphamide-based haploidentical pbsc transplantation with myeloablative conditioning. Biol Blood Marrow Transplant 2016; 22: S81–S82.

    Article  Google Scholar 

  89. Ciurea SO, Lee DA, Cao K, Rondon G, Chen J, Willis DB et al. Phase I trial of IL-21 ex vivo expanded NK cells administration to prevent disease relapse after haploidentical stem-cell transplantation for myeloid leukemias. Blood 2015; 126: 102.

    Article  CAS  Google Scholar 

  90. Thakar M, Hari PN, Keever-Taylor CA, Jones L, Heimfeld S, Sandmaier BM . Donor natural killer (NK) cell immunotherapy following non-myeloablative HLA-haploidentical hematopoietic cell transplantation (HCT) improves relapse and progression free survival (PFS) in patients with hematologic malignancies. Biol Blood Marrow Transplant 2016; 22: S43–S44.

    Article  Google Scholar 

  91. Ovechkina V, Bondarenko S, Morozova E, Slesarchuk O, Stancheva N, Ivanova N et al. Efficiency of hypomethylating agents after allogenic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 2015; 50: S484.

    Google Scholar 

  92. Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A et al. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol 2016; 173: 444–455.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Moiseev IS, Pirogova OV, Alyanski AL, Babenko EV, Gindina TL, Darskaya EI et al. Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus and mycophenolate mofetil. Biol Blood Marrow Transplant 2016; 22: 1037–1042.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Research reported in this publication was supported by the Washington University Institute of Clinical and Translational Sciences grant UL1TR000448, sub-award TL1TR000449, from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.

Author information

Authors and Affiliations

  1. Washington University School of Medicine, St. Louis, MO, USA

    M Slade, B Fakhri & R Romee

  2. Vanderbilt University School of Medicine, Nashville, TN, USA

    B N Savani

Authors
  1. M Slade
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Fakhri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B N Savani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Romee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Romee.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Slade, M., Fakhri, B., Savani, B. et al. Halfway there: the past, present and future of haploidentical transplantation. Bone Marrow Transplant 52, 1–6 (2017). https://doi.org/10.1038/bmt.2016.190

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.190

This article is cited by

Search

Advanced search

Quick links